HLB Co., Ltd. (KOSDAQ:028300)
South Korea · Delayed Price · Currency is KRW 46,050
-1,950 (-4.06%)
Aug 1, 2025, 3:30 PM KST
HLB Co., Ltd. Revenue
HLB Co., Ltd. had revenue of 17.66B KRW in the quarter ending March 31, 2025, with 58.37% growth. This brings the company's revenue in the last twelve months to 74.64B, up 118.00% year-over-year. In the year 2024, HLB Co., Ltd. had annual revenue of 68.13B with 58.80% growth.
Revenue (ttm)
74.64B
Revenue Growth
+118.00%
P/S Ratio
80.94
Revenue / Employee
466.47M
Employees
160
Market Cap
6,040.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.13B | 25.23B | 58.80% |
| Dec 31, 2023 | 42.90B | -136.81B | -76.13% |
| Dec 31, 2022 | 179.71B | 109.88B | 157.37% |
| Dec 31, 2021 | 69.83B | 13.65B | 24.30% |
| Dec 31, 2020 | 56.18B | 17.76B | 46.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| Peptron | 4.30B |
| PharmaResearch | 392.31B |
| Sam Chun Dang Pharm. | 213.08B |